MARKET

DRUG

DRUG

Bright Minds Biosciences Inc
NASDAQ
84.65
-1.90
-2.20%
Closed 17:42 05/12 EDT
OPEN
85.63
PREV CLOSE
86.55
HIGH
86.51
LOW
83.52
VOLUME
126.79K
TURNOVER
0
52 WEEK HIGH
123.75
52 WEEK LOW
23.18
MARKET CAP
828.48M
P/E (TTM)
-42.5762
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DRUG last week (0504-0508)?
Weekly Report · 2d ago
Weekly Report: what happened at DRUG last week (0427-0501)?
Weekly Report · 05/04 09:23
Weekly Report: what happened at DRUG last week (0420-0424)?
Weekly Report · 04/27 09:24
Weekly Report: what happened at DRUG last week (0413-0417)?
Weekly Report · 04/20 09:22
Shroom stocks rise as Trump is said to sign executive order on psychedelic drug
Seeking Alpha · 04/16 16:18
'Trump To Sign Executive Order On Psychedelic Drug Used Abroad To Treat PTSD' - CBS News Exclusive
Benzinga · 04/16 15:56
Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial
TipRanks · 04/16 15:27
Jefferies Initiates Coverage On Bright Minds Biosciences with Buy Rating, Announces Price Target of $145
Benzinga · 04/13 12:21
More
About DRUG
Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.

Webull offers Bright Minds Biosciences Inc stock information, including NASDAQ: DRUG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRUG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DRUG stock methods without spending real money on the virtual paper trading platform.